COX-2 Retrospective Study Prompts Review By FDA, Kaiser On Merck’s Vioxx
A retrospective study conducted on COX-2s and NSAIDs has prompted reviews by FDA and Kaiser Permanente on the use of Merck's Vioxx (rofecoxib)
A retrospective study conducted on COX-2s and NSAIDs has prompted reviews by FDA and Kaiser Permanente on the use of Merck's Vioxx (rofecoxib)